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Omi/HtrA2 is a mammalian serine protease with high
homology to bacterial HtrA chaperones. Omi/HtrA2 is
localized in mitochondria and is released to the cyto-
plasm in response to apoptotic stimuli. Omi/HtrA2 in-
duces cell death in a caspase-dependent manner by in-
teracting with the inhibitor of apoptosis protein as well
as in a caspase-independent manner that relies on its
protease activity. We describe the identification and
characterization of a novel compound as a specific in-
hibitor of the proteolytic activity of Omi/HtrA2. This
compound (ucf-101) was isolated in a high throughput
screening of a combinatorial library using bacterially
made Omi-(134–458) protease and fluorescein-casein as
a generic substrate. ucf-101 showed specific activity
against Omi/HtrA2 and very little activity against vari-
ous other serine proteases. This compound has a natural
fluorescence that was used to monitor its ability to enter
mammalian cells. ucf-101, when tested in caspase-9 (/)
null fibroblasts, was found to inhibit Omi/HtrA2-in-
duced cell death.
Omi/HtrA2 is a human serine protease that has extensive
homology to bacterial high temperature requirement A (HtrA)1
proteins (1, 2). Bacterial HtrAs have a dual function, acting as
chaperones at normal temperatures and as proteases at ele-
vated temperatures and removing damaged or denatured pro-
teins, allowing the recovery and survival of bacteria following
stress (3, 4). Mammalian Omi/HtrA is a ubiquitous protein,
although tissue-specific alternatively spliced forms have been
reported (2, 5). Recent studies (6–10) described Omi as a mi-
tochondrial protein that upon induction of apoptosis is released
to the cytoplasm where it binds XIAP (X chromosome-linked
inhibitor of apoptosis protein) resulting in caspase-9 activation.
In this regard, Omi resembles Smac/DIABLO, which also binds
IAPs and as a result activates caspase-9 (11, 12). Omi protein
is synthesized as a precursor that is processed in the mitochon-
dria to produce the mature protein. This processing exposes an
internal tetrapeptide motif, AVPS, at the amino terminus. A
similar motif is found in all IAP-binding proteins, including the
Drosophila Grim, Reaper, Hid, and Sickle (13–16). Processing
of the precursor Omi polypeptide is an intramolecular reaction
and requires an intact protease domain.2 Omi can also induce
apoptosis in a caspase-independent pathway that relies en-
tirely on its ability to function as a serine protease (6, 7, 9).
Neither the mechanism nor the significance of this function of
Omi is clearly understood. In order to investigate the caspase-
independent mechanism of apoptosis initiated by Omi, we iso-
lated specific inhibitors of its proteolytic activity. One such
family of synthetic compounds was identified and is described
in this paper. These heterocyclic compounds showed significant
and specific activity against the protease in an in vitro assay. A
compound from this family, which exhibited the highest activ-
ity against Omi, was selected for more detailed studies. This
compound (ucf-101) naturally fluoresces and easily enters
mammalian cells, allowing its use in in vivo experiments. Our
results clearly showed ucf-101 had a profound effect on the
activity of Omi and could substantially inhibit its ability to
induce caspase-independent apoptosis in caspase-9 (/) null
fibroblasts (17).
The ucf-101 inhibitor can be used as a tool to dissect the two
different activities (caspase-dependent versus caspase-inde-
pendent) of Omi and their respective contribution to apoptosis
in various biological settings. Furthermore, ucf-101, or a simi-
lar compound, may be useful as an anti-apoptotic drug that
would specifically target caspase-independent cell death under
clinical conditions.
EXPERIMENTAL PROCEDURES
Preparation of FITC-labeled, Dephosphorylated Casein—Dephospho-
rylated-casein (Sigma, 3 ml of 2 mg/ml stock solution) was used in a
dialysis cassette (Pierce) placed in labeling buffer (0.03 mg/ml FITC, 50
mM sodium borate, pH 9.3, 40 mM NaCl) and kept for 48 h at 4 °C in the
dark with constant stirring. After labeling, the FITC-dephosphorylated
casein (Dcasein-FITC) was further dialyzed against 50 mM Tris-HCl,
pH 7.5, and 50 mM NaCl to remove any residual unlabeled FITC. The
Dcasein-FITC conjugate was recovered from the dialysis cassette and
stored at 4 °C in the dark.
Expression and Purification of MBP-Omi and MBP-L56 Proteases—
PCR was used to amplify DNA sequences corresponding to Omi/HtrA2
(amino acids 134–458) and L56/HtrA1 (amino acids 140–480). The
PCR products were digested with MfeI and XbaI and cloned in the
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corresponding EcoRI and XbaI restriction sites of pMAL-p2X vector
(New England Biolabs). MBP-Omi-(134–458) and MBP-L56-(140–480)
proteases were expressed in TB1 Escherichia coli (New England Bio-
labs) and purified on an amylose binding affinity column as described
by the manufacturer (New England Biolabs). The concentration of
purified proteases was determined using the Bradford assay.
Expression and Purification of His-tagged Omi-(134–458)—PCR was
used to amplify the DNA sequence corresponding to Omi/HtrA2 (Omi-
(134–458)). The PCR product was cloned in-frame in the bacterial
expression vector pET-28 (Novagen). For bacterial expression, BL21
(DE3) (Novagen) bacteria were transformed with pET-Omi-(134–458).
Single colonies were grown overnight in LB medium containing kana-
mycin. The overnight culture (1 ml) was used to inoculate 1 liter of LB
medium, and growth was continued at 37 °C until the A600 was0.8. At
this time, 1 mM isopropyl-1-thio--D-galactopyranoside was added, and
the culture was placed in a shaking incubator overnight at 20 °C.
Bacteria were harvested by centrifugation and lysed in a buffer con-
taining 20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 100 g/ml lysozyme, and
a protease inhibitor mixture (Sigma). The bacterial suspension was
then sonicated, and the soluble fraction was purified using nickel-
nitrilotriacetic acid His-Bind resin (Novagen). The purity of the His-
Omi-(134–458) protein was monitored by SDS-PAGE and Coomassie
Blue staining of the resulting gel.
Proteolytic Activity of Omi Using Dcasein-FITC as Substrate—
Opaque microtiter plates (Corning Glass) were used in order to mini-
mize background absorbance. A typical assay included 10 g of Dcasein-
FITC substrate, 2 g of MBP-Omi-(134–458) in assay buffer (20 mM
Na2HPO4/NaH2PO4, pH 7.4, 200 mM NaCl, 5% glycerol) in a final
volume of 100 l. Dcasein-FITC conjugate solution (50 l of a 0.2 g/l
stock solution) was added in each well using a Multidrop 384 multiple
dispenser (Labsystems) and incubated in the Wallac 1420 Victor2 Mul-
tilabel Counter at 37 °C for 15 min. After this time, 50 l of MBP-Omi-
(134–458) protease (40 ng/l) was added to each well. The fluorescence
(535 nm) of the reactions was recorded every 5 min for a 30-min period.
Combinatorial Library Screening—A Pharma Library Collection
(Nanosyn) was screened for compounds, which may inhibit the proteo-
lytic activity of MBP-Omi-(134–458) in an in vitro assay. Each com-
pound, 10 M final concentration, was preincubated with 50 l of
MBP-Omi-(134–458) (2 g) for 15 min at 37 °C. After this time, Dca-
sein-FITC solution (10 g) was added, and the change in fluorescence
was read every 5 min during a 30-min period using a 535-nm bandpass
filter. The proteolytic activity of MBP-Omi-(134–458) was expressed as
the percentage inhibition, where 100% refers to the activity in the
absence of inhibitor (Me2SO replaced the inhibitor in the assay).
Activity of Several ucf Analog Compounds Against MBP-Omi-(134–
458)—The assay was performed as described above using Dcasein-FITC
as substrate. 2 g of MBP-Omi-(134–458) was incubated with various
concentrations of ucf-101, ucf-102, ucf-103, or ucf-104 for 15 min. After
this time 10 g of Dcasein-FITC substrate was added, and the reaction
proceeded for an additional 30 min. The activity of MBP-Omi-(134–
458) was monitored at 535 nm.
Determination of IC50 for ucf-101 and ucf-102—The IC50 value for
each of the two selected inhibitors was obtained using His-Omi-(134–
458) and the EnzCheck assay kit (Molecular Probes) that contains
BODIPY FL-casein as a generic substrate. Briefly, 35 l of His-Omi-
(134–458) (500 nM) diluted in 20 mM Na2HPO4/NaH2PO4, pH 7.4, 200
mM NaCl, 5% glycerol was incubated with 5 l of various concentrations
of the inhibitors (0.1–1000 M) in 100% Me2SO (final concentration of
Me2SO was 10%); 10 l of BODIPY-FL casein (2.5 M final concentra-
tion) diluted in buffer was added. The assay was carried out using
384-well microtiter plates. Fluorescence was monitored continuously
for 10 min at 37 °C on a Tecan SpectraFluorPlus microtiter plate reader
(Tecan, Crailsheim, Germany) at an excitation wavelength 485 nm/
emission wavelength 530 nm. IC50 values were calculated using the
GraFit 4 program (Erithacus Software, Middlesex, UK).
Activity of ucf-101 against Various Serine Proteases—The amount of
the inhibitor giving a 50% (IC50) decrease of the enzyme activity com-
pared with the control reaction was estimated for various serine pro-
teases. Briefly, 35 l of the indicated enzyme diluted in the correspond-
ing buffer was incubated for 10 min with 5 l of various concentrations
of inhibitor (0.1–1000 M) in 50% Me2SO, 50% buffer. After this time, 10
l of the corresponding peptidic colorimetric or fluorogenic substrate
diluted in buffer was added. In the case of the FVIIa/TF assay, a
preincubation of both proteins for 10 min at room temperature was
performed prior to addition of the inhibitor to allow complex formation.
For this experiment the following materials were used: canine FXa, rat
FXa, and rabbit FXa (Enzyme Research Laboratories); trypsin from
bovine pancreas and human thrombin (Sigma); human plasmin, human
t-PA, human u-PA, and human kallikrein (Calbiochem-Novabiochem);
FIG. 1. Chemical structures of ucf-101, ucf-102, ucf-103, and
ucf-104.
FIG. 2. Inhibition of MBP-Omi-(134–458) by ucf-101 and sev-
eral other ucf analogs. The assay was performed with 10 g of
Dcasein-FITC incubated with 2 g of MBP-Omi-(134–458) in the pres-
ence of various concentrations of ucf-101 and three analogs, ucf-102,
ucf-103, and ucf-104. f, ucf-101; Œ, ucf-104; , ucf-103; , ucf-102.
TABLE I
Screening for inhibitors of the proteolytic activity of Omi
A combinatorial library of 528 selected compounds was used in a high
throughout screening for potential inhibitors of the proteolytic activity
of Omi. Several compounds had weak activity against Omi, but after
two rounds of selection only one chemical showed substantial and
reproducible inhibition against Omi in the assay used.
% inhibition 1st screening 2nd screening
0 6 26
1–19 468 47
20–39 52 1
40–59 2 1
Total 528 75
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human APC and recombinant human factor VIIa (American Diagnos-
tica); and recombinant tissue factor (Dade Behring). The substrates
used are as follows: spectrozyme fXa fluorogenic (American Diagnos-
tica); kallikrein fluorogenic substrate; protein C-activated substrate
(Calbiochem); Chromozym X, Chromozym PL, and Chromozym t-PA
(Roche Diagnostics); I-1045, I-1140, and I-1140 (Bachem).
The amount of each enzyme and its corresponding substrate used in
the assay was canine FXa (2 nM), spectrozyme fXa fluorogenic (20 M), rat
FXa (5 nM), spectrozyme fXa fluorogenic (25 M), rabbit FXa (5 nM),
spectrozyme fXa fluorogenic (15 M), kallikrein (5 nM), kallikrein fluoro-
genic substrate (50 M), trypsin (2.5 nM), Chromozym X (150 M), plasmin
(5 nM), I-1045 (100 M), thrombin (4 nM), Chromozym PL (150 M),
FVIIa/tissue factor (15 nM/3 nM), Chromozym t-PA (500 M), t-PA (100
nM), I-1140 (200 M), u-PA (3 nM), I-1140 (150 M), activated protein C (5
nM), and protein C-activated substrate (100 M) in a final concentration of
5% Me2SO. All enzymatic assays were carried out at room temperature in
384-well microtiter plates (Nunc). Color development due to the release of
p-nitroanilide from the chromogenic substrates was monitored continu-
ously for 20 min at 405 nm on a Tecan SpectraFluorPlus microtiter plate
reader (Tecan). Fluorescence from the release of the coumarin derivative,
aminomethylcoumarin, was measured at excitation 360 nm/emission 465
nm on the same reader. The IC50 values were calculated using the GraFit
4 program (Erithacus Software).
Subcellular Localization of ucf-101—HeLa cells were grown on cov-
erslips using F-12 (Ham’s) nutrient mixture (Invitrogen) supplemented
with 10% fetal calf serum (Sigma), 2 mM L-glutamine, 100 units/ml
penicillin, and 100 g/ml streptomycin (Invitrogen). Different concen-
trations of ucf-101 were added to the cell media, and after 2 h cells were
washed three times with phosphate-buffered saline and fixed with 4%
paraformaldehyde. The coverslips were then placed on glass slides
using Fluoromount-G solution (Southern Biochemical Association). The
subcellular localization of ucf-101 was monitored using a LSM510 con-
focal laser-scanning microscope (Zeiss).
ucf-101 Inhibits Omi-induced Caspase-independent Apoptosis in
Caspase-9 (/) Null Fibroblasts—Caspase-9 (/) cells were trans-
fected with either pEGFP-N1 vector (Clontech) or M-Omi-GFP that
encodes a cytoplasmic form of Omi/HtrA2 (7). Transfected cells were
kept in medium containing different concentrations of ucf-101. This
medium, including the inhibitor, was replaced every 12 h. After 36 h,
cells were stained with propidium iodide and 4,6-diamidino-2-phe-
nylindole as described (7). Normal and apoptotic GFP-expressing cells
were counted using fluorescence microscopy.
RESULTS
Activity of Omi Protease against Dcasein-FITC—Because no
physiological substrates for Omi protease are known, -casein
was used as a generic substrate in in vitro assays to monitor
the protease activity of Omi. For high throughput screening, we
developed a new assay that uses a mixture of -casein, -ca-
sein, and dephosphorylated casein (Dcasein) coupled to FITC,
as a substrate. The use of Dcasein-FITC increases the fluores-
cence during the reaction with less fluctuation and lower back-
ground (data not shown). A typical assay uses 10 g of Dcasein-
FITC and 2 g of MBP-Omi-(134–458) in 100 l of reaction
buffer (20 mM sodium phosphate buffer, pH 7.5, 200 mM NaCl,
and 5% glycerol) at 37 °C for 30 min. There was a rapid in-
crease in fluorescence for the first 20 min followed by a slower
FIG. 3. In vitro assay of the proteolytic activity of His-Omi-(134–
458) in the presence of different concentrations of ucf-101. The
assay was performed at 37 °C, and after the indicated time points the
reactions were resolved on SDS-PAGE and the gel stained with Coomas-
sie Blue. Omi (200 ng) was incubated with 5 g of -casein substrate in a
20-l reaction volume for 30 min at 37 °C. The ucf-101 compound was
preincubated with His-Omi-(134–458) (His-Omi) protease for 10 min at
room temperature prior to the addition of -casein substrate. Lane 1,
-casein control; lane 2, His-Omi  -casein, digested for 15 min; lane 3,
His-Omi  -casein, digested for 30 min; lane 4, His-Omi  100 M
ucf-101  -casein; lane 5, His-Omi  80 M ucf-101  -casein; lane 6,
His-Omi  50 M ucf-101  -casein; lane 7, His-Omi  30 M ucf-101 
-casein; lane 8, His-Omi  20 M ucf-101  -casein; lane 9, His-Omi 
10 M ucf-101  -casein; and lane 10, prestained molecular weight
marker.
FIG. 4. Inhibition of the proteolytic activity of MBP-Omi-(134–
458) and MBP-L56-(140–480) by ucf-101. The assay was performed
with 10 g of FITC-Dcasein and 2 g of MBP-Omi-(134–458) (MBP-
Omi) or MBP-L56-(140–480) (MBP-L56) in the presence of various
concentrations of ucf-101. The increase in fluorescence for the initial 20
min was used for comparing the activities of MBP-Omi-(134–458) or
MBP-L56-(140–480). , MBP-Omi; f, MBP-L56.
TABLE II
IC50 of ucf-101 and ucf-102 inhibitors on His-Omi
The value is the average from three independent experiments.
Inhibitors IC50 in M
ucf-101 9.5
ucf-102 45.9
TABLE III
IC50 values of ucf-101 on various proteases
The two IC50 values are derived from two independent experiments.
Protease IC50 in M
Canine-FXa 430
360
Rat-FXa 410
500
Rabbit-FXa 260
300
Hu-kallikrein 200
250
Bovine-trypsin 500
500
Hu-plasmin 500
400
Hu-thrombin 500
500
Hu-rec.-FVIIa 500
500
Hu-t-PA 390
390
Hu-u-PA 500
500
Hu-APC 500
500
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increase for the remaining 10 min of the assay. Various con-
centrations of substrate, Dcasein-FITC, as well as MBP-Omi-
(134–458) were used for kinetic studies.
Combinatorial Library Screening—By using an in vitro high
throughput assay system, we screened a combinatorial library
of synthetic compounds (Nanosyn). This collection represented
compounds that had commonly accepted pharmaceutical hit
structures with possible pharmacological properties. The assay
was performed in multiple 96-well plates. The inhibition activ-
ity of each compound was expressed as the percentage of rela-
tive fluorescence change (decrease) compared with the control
(no compound). The final concentration of each compound
tested was 10 M. Fifty two compounds showed more than a
20% inhibition of MBP-Omi-(134–458) activity in the initial
screening, but only one compound (ucf-101) showed greater
than a 50% inhibition at the concentration tested after two
rounds of screening and selection (Table I).
Inhibition of the Proteolytic Activity of MBP-Omi-(134–458)
Using ucf-101 and Various Analogs—We obtained several an-
alogs of ucf-101, and the chemical structures are shown in Fig.
1. The activity of these ucf analogs was tested using MBP-Omi-
(134–458) in the same in vitro assay system. All three analogs
inhibited the proteolytic activity of MBP-Omi-(134–458) but to
a lesser extent than ucf-101 (Fig. 2). ucf-104 (20 M) inhibited
58% MBP-Omi-(134–458) activity, whereas the same concen-
tration of ucf-101 inhibited more than 78% MBP-Omi-(134–
458) activity. When MBP-Omi-(134–458) was preincubated
with various concentrations of ucf-101, -102, -103, and -104 at
37 °C for longer periods (40 min or 1 h) inhibition was reduced,
indicating the inhibitors did not irreversibly bind the enzyme
(results not shown). MBP-Omi-(134–458) was also incubated
with various amounts of Dcasein-FITC in the presence of 10 M
ucf-101. The rate of the reaction decreased by 50% when the
concentration of the substrate was doubled and even reached
the rate of the control reaction at higher concentrations of
Dcasein-FITC (results not shown). These results suggest ucf-
101 is a competitive inhibitor of Omi protease.
Assay of His-Omi-(134–458) Activity Using Unlabeled -Ca-
sein and SDS-PAGE Analysis—The inhibitory effect of ucf-101
on the activity of His-Omi-(134–458) was monitored by incu-
bating inhibitor and enzyme together for 10 min at room tem-
perature prior to the addition of -casein as a generic sub-
strate. Fig. 3 shows that bacterially made His-Omi-(134–458)
had substantial activity against -casein, and after 30 min
total degradation of the substrate occurred. ucf-101 inhibited
His-Omi-(134–458) activity in a concentration-dependent
manner (lanes 4–9) when assayed for 30 min with 200 ng of
His-Omi-(134–458) and 5 g of -casein. ucf-101 (80 M) was
able to inhibit completely the activity of 200 ng of His-Omi-
(134–458) (lane 5).
Comparison of the Proteolytic Activities of His-Omi-(134–
458) and His-L56-(156–480) Proteins—Omi/HtrA2 and L56/
FIG. 5. Cytoplasmic localization of
ucf-101. Subconfluent HeLa cells were
treated with 50 (A), 40 (B), and 20 M (C)
ucf-101 and were observed using a confo-
cal microscope. A–C show cytoplasmic red
staining due to the presence of ucf-101,
indicating cells are permeable to this
chemical. D, no staining was seen when
Me2SO alone was used.
FIG. 6. Inhibition of Omi-induced caspase independent cell
death by ucf-101. Caspase-9 (/) fibroblasts were transfected with
pEGFP or M-Omi-EGFP (7) and kept in media containing different
concentrations of ucf-101. The percentage of apoptotic cells in the trans-
fected population was determined after 36 h as described (7).
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HtrA1 are members of the same family of mammalian serine
proteases with extensive homology in their catalytic domains
(1). We used bacterially made His-Omi-(134–458) and His-
L56-(140–480) to investigate whether ucf-101 was able to in-
hibit the activity of His-L56-(140–480) in a similar manner.
Fig. 4 shows ucf-101 is an effective inhibitor of the activity of
His-L56-(140–480) but to a lesser extent than His-Omi-
(134–458).
IC50 of ucf-101 against Various Serine Proteases—The enzy-
matic activity of His-Omi and the determination of the IC50 for
ucf-101 and ucf-102 were performed as described under “Ex-
perimental Procedures.” These values are shown in Table II.
ucf-101 had an IC50 of 9.5 M, and ucf-102 had an IC50 of 45.9
M.
The specificity of ucf-101 was determined using several un-
related serine proteases. Their susceptibility to inhibition by
ucf-101 was tested. The IC50 values for ucf-101 inhibitor from
these experiments are shown in Table III. These results sug-
gest ucf-101 has very high specificity for the Omi protease.
Intracellular Localization of ucf-101—To investigate the po-
tential use of ucf-101 inhibitor in in vivo experiments, we
tested its ability to enter mammalian cells. ucf-101 has natural
fluorescence at 543 nm that was used to detect the presence of
the compound. HeLa cells were treated with different concen-
trations of ucf-101 and observed by confocal microscopy. In-
tense red fluorescence, due to the presence of ucf-101, was
observed in the cytoplasm of the treated cells (Fig. 5)
ucf-101 Can Inhibit Omi-induced Caspase-independent Apo-
ptosis—Mouse embryo caspase-9 (/) null fibroblasts (17)
were transiently transfected with pEGFP-N1 (control) or M-
Omi-GFP (7). Cytoplasmic expression of M-Omi-GFP induced
apoptosis in 70% of the transfected cells. When cells were
treated with increasing concentrations of ucf-101, it was found
that increasing the concentration of inhibitor up to 10 M
gradually reduced Omi-induced apoptosis up to 40%. ucf-101
had no effect on the control (vector alone) transfected cells.
When the concentration of the ucf-101 increased to 25 M, the
anti-apoptotic activity of the inhibitor was compromised due to
a cytotoxic side effect that caused apoptosis both in the M-Omi-
GFP, as well as control transfected cells (Fig. 6).
DISCUSSION
Omi/HtrA2 is a mitochondrial serine protease that is re-
leased to the cytoplasm upon induction of apoptosis. In the
cytoplasm, Omi binds to XIAP and relieves its inhibition of
caspase-9 (6, 7, 9). In this respect, Omi acts in a manner similar
to Smac/DIABLO, another mitochondrial protein that also
binds to XIAP (11, 12). This interaction with XIAP is mediated
via an AVPS motif that is exposed at the amino terminus of
mature Omi protein after processing (6, 7). Omi is also able to
induce apoptosis in a caspase-independent manner that exclu-
sively relies on its ability to function as a protease (6–10). This
caspase-independent pathway is not well understood; its con-
tribution to overall cell death is not known, and the role of Omi
as a protease in this pathway is not clear. Furthermore, al-
though the catalytic domain of all HtrAs including Omi protein
is conserved from E. coli to humans, the AVPS tetrapeptide is
replaced at least in bovine Omi by SVLG (18). This suggests the
IAP binding activity of human HtrA2 that leads to caspase-de-
pendent apoptosis may not be critical to the overall function of
Omi. Because the caspase-independent pathway relies on the
ability of Omi to function as a protease, it suggests that pro-
teolytic cleavage of specific proteins is involved. This cleavage
might inactivate and remove apoptotic inhibitors, or it may
activate precursor proteins whose function might be necessary
for caspase-independent cell death. In order to investigate the
contribution of the proteolytic activity of Omi to its overall
pro-apoptotic function, we decided to screen for specific inhib-
itor(s) of its activity. One such specific inhibitor was identified
and called ucf-101. This heterocyclic compound was able to
inhibit the proteolytic activity of Omi in vitro in a very specific
and reversible manner. The specificity of ucf-101 was tested
against a panel of several unrelated serine proteases, and no
significant activity was detected. When L56/HtrA1 was used in
the same assay, ucf-101 showed specific inhibition against this
protease. L56/HtrA1 belongs to the same family of proteases as
Omi, and they both share extensive homology throughout their
respective catalytic domains (1). The normal function of L56/
HtrA2 is not known, and unlike Omi that localizes to mitochon-
dria, L56 is secreted (19). The natural fluorescence of ucf-101
was used to monitor its ability to enter mammalian cells. This
property is essential for ucf-101 to be useful for in vivo exper-
iments designed to test inhibition of Omi that is intracellular.
To test the ability of ucf-101 to inhibit the proteolytic activity of
Omi in vivo, we used an assay where transient overexpression
of a cytoplasmic form of Omi induces caspase-independent
cell death (7). The cells used in this assay were caspase-9
(/) null mouse embryonic fibroblasts (17) in which over-
expression of a cytoplasmic form of Omi can induce the
caspase-independent pathway of apoptosis. This form of cell
death caused by Omi relies entirely on its ability to function
as a protease. Therefore, if ucf-101 blocks the activity of Omi,
it will interfere with apoptosis of the caspase-9 (/) mouse
embryonic fibroblasts. When these fibroblasts were trans-
fected with the vector encoding the cytoplasmic Omi and
treated with ucf-101, apoptosis was dramatically reduced.
ucf-101, like many known protease inhibitors, was cytotoxic
to mammalian cells when used at high concentrations. There-
fore, the ability of ucf-101 to inhibit caspase-independent
apoptosis at low doses was compromised by its cytotoxicity at
higher doses. This toxicity was seen only at high concentra-
tions of the chemical and does not exclude its use in in vivo
experiments where it exhibits activity against Omi at much
lower concentrations. ucf-101 will be a useful tool to elucidate
the role of Omi in caspase-independent cell death. Several
clinical conditions, such as neurodegenerative diseases, show
excessive caspase-independent cell death (20, 21). If Omi
through its proteolytic activity plays a role in the pathogen-
esis of any of these clinical conditions, ucf-101 or a similar
compound would be useful for therapeutic intervention
against untimely or excessive cell death.
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